FDA lifts hold on Covaxin's clinical trials in US

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab.

Published: 24th May 2022 07:10 PM  |   Last Updated: 24th May 2022 07:10 PM   |  A+A-

A health worker shows the vials fo Covaxin dose, at a vaccination centre in Kolkata. (Photo | PTI)

A health worker shows vials of Covaxin at a vaccination centre. (Photo | PTI)

By PTI

HYDERABAD: The US Food and Drug Administration which has put on hold the phase 2/ 3 clinical trials of Bharat Biotech's COVID-19 vaccine Covaxin, in USA, has lifted the pause, according to a statement issued by Ocugen Inc, Bharat Biotech's partner for the jab in USA and Canada.

"We're extremely pleased that we can proceed with our clinical trials for Covaxin our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority," Dr Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen Inc said.

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation's observations on Covaxin manufacturing plants in India.

"Thank you to our clinical trial partners and site collaborators for their ongoing support. Ocugen will now work with study sites to fully resume this clinical development program immediately," he further said.

WHO had earlier suspended the supply of Covaxin through US procurement agencies, after its inspectors identified GMP (good manufacturing practice) deficiencies in the Bharat Biotech's manufacturing plants.

Sources had said the city-based firm however, had not supplied the Covid vaccine to any UN agency and no impact of the suspension would be felt.

OCU-002 is Ocugen's Phase 3 immuno-bridging study of Covaxin.

After the WHO inspection, Bharat Biotech had said it is temporarily slowing down the production of Covaxin across its manufacturing units for facility optimisation as it has already completed its supply obligations to procurement agencies and foresees a decrease in demand.

The company further said after the recent WHO post-Emergency Use Listing (EUL) inspection, it is working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever-increasing global regulatory requirements.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp